Chronic lymphocytic leukemia (CLL) is one of the most common types of leukemia in adults — DOCK2 is a key protein in cell signaling pathways that contributes to the development and progression of CLL. Dr. Hasan’s research suggests that DOCK2 could be neutralized by an antibody called cirmtuzumab or inhibitors called ibrutinib/acalabrutinib. In fact, combining the two may become the answer to treating CLL, and this TCRF-funded project will provide the research support necessary to make such a treatment possible, which would improve the quality of life of CLL and related blood cancer patients.